Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria Cristina Riascos"'
Autor:
Yanping Yang, Huan Yang, Yago Alcaina, Janusz Puc, Alyssa Birt, Yogindra Vedvyas, Michael Gallagher, Srinija Alla, Maria Cristina Riascos, Jaclyn E. McCloskey, Karrie Du, Juan Gonzalez-Valdivieso, Irene M. Min, Elisa de Stanchina, Matt Britz, Eric von Hofe, Moonsoo M. Jin
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract The limited number of targetable tumor-specific antigens and the immunosuppressive nature of the microenvironment within solid malignancies represent major barriers to the success of chimeric antigen receptor (CAR)-T cell therapies. Here, us
Externí odkaz:
https://doaj.org/article/1773c1a113ad431dbfb194f4da0fc107
Autor:
Jessica Limberg, Caitlin E. Egan, Katherine D. Gray, Mandeep Singh, Zachary Loewenstein, Yanping Yang, Maria Cristina Riascos, Hala Al Asadi, Parima Safe, Steve El Eshaky, Heng Liang, Timothy M. Ullmann, Weibin Wang, Wei Li, Tuo Zhang, Jenny Xiang, Dessislava Stefanova, Moonsoo M. Jin, Rasa Zarnegar, Thomas J. Fahey, Irene M. Min
Publikováno v:
Molecular Cancer Research. 21:397-410
A subset of thyroid cancers, recurrent differentiated thyroid cancers and anaplastic thyroid cancer (ATC), are difficult to treat by thyroidectomy and systemic therapy. A common mutation in thyroid cancer, BRAFV600E, has targetable treatment options;
Autor:
Irene M. Min, Thomas J. Fahey, Rasa Zarnegar, Moonsoo M. Jin, Dessislava Stefanova, Jenny Xiang, Tuo Zhang, Wei Li, Weibin Wang, Timothy M. Ullmann, Heng Liang, Steve El Eshaky, Parima Safe, Hala Al Asadi, Maria Cristina Riascos, Yanping Yang, Zachary Loewenstein, Mandeep Singh, Katherine D. Gray, Caitlin E. Egan, Jessica Limberg
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08c03a3039ae476a972e72bf0da1627b
https://doi.org/10.1158/1541-7786.22725440.v1
https://doi.org/10.1158/1541-7786.22725440.v1
Autor:
Irene M. Min, Thomas J. Fahey, Rasa Zarnegar, Moonsoo M. Jin, Dessislava Stefanova, Jenny Xiang, Tuo Zhang, Wei Li, Weibin Wang, Timothy M. Ullmann, Heng Liang, Steve El Eshaky, Parima Safe, Hala Al Asadi, Maria Cristina Riascos, Yanping Yang, Zachary Loewenstein, Mandeep Singh, Katherine D. Gray, Caitlin E. Egan, Jessica Limberg
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to paren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13b6b2bf942c9fc01ea3a25256b6cd0c
https://doi.org/10.1158/1541-7786.22725437
https://doi.org/10.1158/1541-7786.22725437
Autor:
Irene M. Min, Thomas J. Fahey, Rasa Zarnegar, Moonsoo M. Jin, Dessislava Stefanova, Jenny Xiang, Tuo Zhang, Wei Li, Weibin Wang, Timothy M. Ullmann, Heng Liang, Steve El Eshaky, Parima Safe, Hala Al Asadi, Maria Cristina Riascos, Yanping Yang, Zachary Loewenstein, Mandeep Singh, Katherine D. Gray, Caitlin E. Egan, Jessica Limberg
A subset of thyroid cancers, recurrent differentiated thyroid cancers and anaplastic thyroid cancer (ATC), are difficult to treat by thyroidectomy and systemic therapy. A common mutation in thyroid cancer, BRAFV600E, has targetable treatment options;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7db8dedaf7a0db58a32cdf502c9936a
https://doi.org/10.1158/1541-7786.c.6545598.v1
https://doi.org/10.1158/1541-7786.c.6545598.v1
Autor:
Yanping Yang, Yago Alcaina, Yogindra Vedvyas, Maria Cristina Riascos, Edward K. Fung, Brett Vaughn, Sarah M. Cheal, Irene M. Min, Claire Vanpouille-Box, Moonsoo M. Jin
Publikováno v:
Cancer Research. 83:5084-5084
Purpose: Current understanding of resistance to CAR-T cell therapy in solid tumors implicates inadequate CAR-T cell potency in the immunosuppressive tumor microenvironment (TME). We have previously developed a platform using somatostatin receptor 2 (
Autor:
Rodrigo C. Edelmuth, Federico Palacardo, Jacques A. Greenberg, Caitlin Egan, Yeon Joo Lee, Maria Cristina Riascos, Murtaza Qazi, Felice Schnoll-Sussman, Philip O. Katz, Brendan M. Finnerty, Thomas J. Fahey, Rasa Zarnegar
Publikováno v:
Gastroenterology. 162:S-1328